Janus Kinase Inhibitors: What You Need To Know In 2025
Janus kinase inhibitors revolutionise treatment of inflammatory skin diseases with targeted oral and topical therapies.
Author: Dr Amanda Oakley, Dermatologist, Hamilton, New Zealand. Reviewed: January 2025.
What are janus kinase inhibitors?
Janus kinase inhibitors (JAKi), also known as jakinibs, are a class of small-molecule medications that target enzymes involved in the signalling pathways of several growth factors and cytokines. These pathways are crucial in immune responses and inflammation, making JAKi highly effective for immune-mediated skin diseases.
The JAK-STAT signalling pathway transmits information from extracellular chemical signals (cytokines and growth factors) to the cell nucleus to influence DNA transcription. JAK family enzymes include JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2). Cytokines bind to receptors, activating specific JAK enzymes, which phosphorylate STAT proteins. These STAT dimers then translocate to the nucleus to regulate gene expression.
Dysregulation of this pathway contributes to inflammatory dermatoses. JAK inhibitors block JAK enzymes, preventing STAT activation and downstream inflammatory effects. Their small molecular size allows both oral and topical formulations, providing advantages over biologics by interrupting multiple cytokine signals simultaneously.
Drug development
The first JAK inhibitor, tofacitinib, received FDA approval in 2012 for rheumatoid arthritis, later expanding to psoriatic arthritis and ulcerative colitis. Dermatology approvals followed: abrocitinib and upadacitinib for atopic dermatitis (2021–2022), baricitinib for alopecia areata (2022), ruxolitinib cream for vitiligo (2022), and deucravacitinib for psoriasis (2022).
Development focuses on selectivity: pan-JAK inhibitors (e.g., tofacitinib: JAK1/3) versus selective ones (e.g., deucravacitinib: TYK2 allosteric inhibitor). Topical formulations enhance skin penetration for localised therapy.
What are the indications for janus kinase inhibitors?
JAKi are approved or investigated for numerous dermatological conditions (see table below):
| Indication | Approved for use | Under investigation |
|---|---|---|
| Atopic dermatitis | Abrocitinib (oral) Upadacitinib (oral) Ruxolitinib (topical) | |
| Alopecia areata | Baricitinib (oral) | |
| Vitiligo | Ruxolitinib (topical) | |
| Plaque psoriasis | Deucravacitinib (oral) | |
| Prurigo nodularis | Abrocitinib (oral) | |
| Chronic hand dermatitis | Delgocitinib (topical) | |
| Granulomatous disorders (sarcoidosis, granuloma annulare, necrobiosis lipoidica) | Tofacitinib (oral) | |
| Other investigated uses | Psoriasis, hidradenitis suppurativa, dermatomyositis, lichen planus, sarcoidosis, graft-versus-host disease |
Atopic dermatitis
Moderate-to-severe atopic dermatitis (AD) responds rapidly to JAKi due to their blockade of itch- and inflammation-driving cytokines (IL-4, IL-13, IL-31 via JAK1; IL-2, IL-15 via JAK1/3). Oral abrocitinib (JAK1) and upadacitinib (JAK1) achieve EASI-75 in 60–70% of patients by week 16, faster than biologics. Topical ruxolitinib (JAK1/2) yields clear/almost clear skin in 50% by week 8.
JADE trials for abrocitinib showed rapid itch reduction within days. SELECT-AD trials for upadacitinib confirmed sustained efficacy up to 52 weeks with flexible dosing.
Alopecia areata
Alopecia areata (AA) involves IFN-γ-driven JAK1/2 and IFN-α/λ-driven JAK1/TYK2 pathways in hair follicles. Baricitinib (JAK1/2) is FDA-approved for severe AA. BRAVE-AA1/2 phase 3 trials reported 35–40% SALT score ≤20 (≥80% scalp hair coverage) at week 36 versus 1–3% placebo.
Real-world data supports efficacy in totalis/universalis AA, with hair regrowth starting at 4–12 weeks.
Vitiligo
Vitiligo pathogenesis features elevated IFN-γ/CXCL10 via JAK1/2. Topical ruxolitinib 1.5% cream (JAK1/2) is FDA-approved for non-segmental vitiligo. TRuE-V1/2 trials showed 50% facial F-VASI improvement at week 52 in 30% of patients versus 10% vehicle.
Topical tofacitinib and ifidancitinib show promise in pilot studies, with better repigmentation in darker skin types and facial lesions. Oral ruxolitinib/upadacitinib aid extensive disease.
Psoriasis
Deucravacitinib (TYK2 allosteric inhibitor) targets IL-12/23, IL-23 pathways. POETYK PSO-1/2 phase 3 trials demonstrated PASI-75 in 58–69% at week 16 versus 13–18% placebo, superior to apremilast. Sustained responses at week 52 with once-daily dosing.
Off-label tofacitinib shows variable efficacy; pan-JAKi may risk herpes zoster reactivation.
Prurigo nodularis
Abrocitinib approval stems from phase 3 trials showing rapid pruritus reduction and nodule clearance via IL-4/IL-31 blockade.
Other conditions
- Hidradenitis suppurativa: Upadacitinib phase 2 trials report HiSCR-50 in 60%.
- Lichen planus/planopilaris: Oral tofacitinib/ruxolitinib induce remission in case series via IFN-γ suppression.
- Sarcoidosis: Tofacitinib achieves skin/pulmonary remission in open-label trials.
- Graft-versus-host disease: Ruxolitinib FDA-approved systemically; topical for cutaneous.
- Dermatomyositis: Tofacitinib improves skin/muscle via IFN blockade.
What are the adverse effects of janus kinase inhibitors?
JAKi carry boxed warnings for serious infections, malignancy, thrombosis, cardiovascular events, and mortality (post-marketing data from rheumatology). Risks increase with age >50, cardiovascular factors, malignancy history.
| Drug | Target | Common AEs | Serious risks |
|---|---|---|---|
| Abrocitinib | JAK1 | Nausea, headache, acne | Infections, HZ, VTE |
| Upadacitinib | JAK1 | Acne, HZ, URTI | MACE, malignancy |
| Baricitinib | JAK1/2 | URTI, acne, elevated CK | Infections, thrombosis |
| Ruxolitinib (topical) | JAK1/2 | Application site reactions, acne | Systemic absorption low |
| Deucravacitinib | TYK2 | URI, folliculitis | Fewer serious AEs |
Topical agents have fewer systemic effects. Monitor lipids, CBC, LFTs; vaccinate for HZ/Shingrix.
Drug interactions
CYP3A4 inhibitors increase levels (e.g., ketoconazole). Avoid strong inducers (rifampicin). Live vaccines contraindicated.
Interactions with other drugs
Caution with biologics, other immunosuppressants (increased infection risk). Statins for lipid elevations.
What is the outcome for patients taking janus kinase inhibitors?
Rapid onset (days for itch, weeks for lesions) surpasses biologics. Durable responses with continuation; relapse on discontinuation varies (faster in AA/vitiligo). Long-term safety data emerging; TYK2 inhibitors potentially safer.
Which topical agents are available on prescription?
- Ruxolitinib 1.5% cream (vitiligo, atopic dermatitis)
- Delgocitinib ointment (chronic hand dermatitis, Japan)
Frequently asked questions
Are JAK inhibitors safe long-term?
Long-term data (up to 4 years) show sustained efficacy but require monitoring for infections, MACE, malignancy per boxed warnings.
Who should avoid JAK inhibitors?
Patients >65, smokers, CVD/malignancy history, active infections, pregnancy.
How quickly do they work?
Itch relief in days; visible improvement in 2–4 weeks, superior to biologics.
Can they cure diseases?
No, they control inflammation; relapse common on stopping.
Topical vs oral?
Topical for localised disease (lower systemic risk); oral for extensive.
References
- Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus… — Indian J Dermatol Venereol Leprol. 2023. https://ijdvl.com/janus-kinase-inhibitors-in-dermatology-a-review-of-their-use-in-psoriasis-vitiligo-systemic-lupus-erythematosus-hidradenitis-suppurativa-dermatomyositis-lichen-planus-lichen-planopilaris-sarco/
- Presenting JAK inhibitor safety information to dermatology patients — J Vasc Med. 2024-10-29. https://onlinelibrary.wiley.com/doi/full/10.1002/jvc2.551
- A practical guide to using oral Janus kinase inhibitors for atopic dermatitis — Br J Dermatol. 2024-12-06. https://academic.oup.com/bjd/article/192/1/135/7754126
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology — PMC. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11610805/
- Janus kinase inhibitors – DermNet — DermNet NZ. 2025-01. https://dermnetnz.org/topics/janus-kinase-inhibitors
Similar Articles
Read full bio of medha deb
